858 Therapeutics
Carlo Rizzuto is a Partner based in New York City. Since joining the firm as a Principal in 2012, he has been involved in building and investing in a number of Versant’s portfolio companies including Pandion (PAND, acquired), Repare (RPTX), Century Therapeutics (IPSC), Graphite Bio (GRPH), Jnana, 858 Therapeutics, VenatoRx and Stablix. Carlo has been instrumental in establishing Versant’s presence in the Northeast. Prior to opening the NYC office, he was based in Versant’s Basel office. Carlo joined Versant from Novartis where he led global product development teams advancing innovative new medicines. Prior to his role at Novartis, he held the position of Associate Principal with McKinsey & Company, advising U.S. and European clients in the pharmaceutical, payor and provider sectors.
Carlo holds a Ph.D. in virology from Harvard University.
This person is not in the org chart
This person is not in any offices
858 Therapeutics
858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule drugs that act on novel therapeutic targets in oncology, including proteins that regulate RNA and the innate immune response.